The parasite clearance curve by White NJ

Get full text

Bacteremia in adults with severe malaria by White, NJ

Reply to Aung et al. by White, NJ

Declining malaria transmission and pregnancy outcomes in southern Mozambique by White, NJ

What causes malaria anemia? by White, NJ

The assessment of antimalarial drug efficacy in vivo by White, NJ

Triple artemisinin-containing combination anti-malarial treatments should be implemented now to delay the emergence of resistance by White, NJ

The antimalarial activity of tafenoquine in falciparum malaria by White, NJ

Severe malaria by White, NJ

Malaria parasite clearance by White, NJ

Anti-malarial drug effects on parasite dynamics in vivax malaria by White, NJ

The prevention and treatment of Plasmodium vivax malaria by Chu, CS, White, NJ

Antimalarial mass drug administration: ethical considerations by Cheah, PY, White, NJ

SERCAP: is the perfect the enemy of the good? by White, NJ, Nosten, FH

Higher-dose primaquine to prevent relapse of Plasmodium vivax malaria by Watson, JA, White, NJ

COVID-19 chemoprevention by Cruz, C, White, NJ

Is malaria parasite ex-vivo viability reduction really “superior” to observed parasite clearance rate? by White, NJ, Watson, JA

Does hydroxychloroquine still have any role in the COVID-19 pandemic? by Schilling, WH, White, NJ

Advances and roadblocks in the treatment of malaria by Hanboonkunupakarn, B, White, NJ

Questioning the claimed superiority of malaria parasite ex vivo viability reduction over observed parasite clearance rate?  by White, NJ, Watson, JA